Measurable residual disease (MRD) before hematopoietic cell transplantation (HCT) is an independent established prognostic factor in patients with acute myeloid leukemia (AML). Several methods exist to evaluate the presence of residual leukemia cells, but how these are used best in combination is unclear. To examine how residual cytogenetic abnormalities and MRD testing by multiparameter flow cytometry (MFC) may refine risk assessment before HCT, we analyzed 506 adults with cytogenetically abnormal AML who underwent both routine karyotyping and MFC MRD testing before receiving a first allograft while in morphologic remission. Testing for residual cytogenetic abnormalities and MFC MRD identified four groups of patients with differential relapse-free survival (RFS, hazard ratio [HR]=1.63 for Cytoabnormal/MFCnegative [P=0.01, n=63], HR=3.24 for Cytonormal/MFCpositive [P.

中文翻译：

---

残余细胞遗传学异常和流式细胞术可测量的残余疾病对成人急性髓性白血病异基因造血细胞移植后结果的相对影响。

造血细胞移植 (HCT) 前的可测量残留病灶 (MRD) 是急性髓系白血病 (AML) 患者的独立预后因素。有几种方法可以评估残留白血病细胞的存在，但如何最好地结合使用这些方法尚不清楚。为了检查通过多参数流式细胞术 (MFC) 进行的残留细胞遗传学异常和 MRD 测试如何改进 HCT 前的风险评估，我们分析了 506 名患有细胞遗传学异常 AML 的成年人，他们在接受第一次同种异体移植之前接受了常规核型分析和 MFC MRD 测试，同时处于形态学缓解期。对残留细胞遗传学异常和 MFC MRD 的检测确定了四组具有差异无复发生存期的患者（RFS，细胞异常/MFC 阴性的风险比 [HR] = 1.63 [P = 0.01，n = 63]，HR = 3。